Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
HTRA1	5654	HYDROGEN PEROXIDE	CHEMBL71595		NCI	10517331
HTRA1	5654	BEVACIZUMAB	CHEMBL1201583		PharmGKB

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
HTRA1	rs11200638	AA	bevacizumab	efficacy	yes	as determined by lower changes in visual acuity score. AG heterozygotes seemed to have higher changes than GG homozygotes. This variant was not associated with significant difference in central retinal thickness or max. lesion thickness.	Genotype AA is associated with decreased response to bevacizumab in people with Macular Degeneration as compared to genotype GG.	22594510	827919998
HTRA1	rs11200638	AA	bevacizumab	efficacy	no	No significant differences in mean visual acuity (units = letters), mean visual acuity change from baseline (units = letters), >= 15-letter increase from baseline (%), mean number of injections, retinal thickness (%, units = um), mean change in total foveal thickness from baseline (units = um), dry on optical coherence tomography (%), leakage on fluorescein angiography (%) or mean change in lesion size from baseline (units = disc area) after 1 year of treatment were seen between genotypes. p <= 0.01 was considered statistically significant to adjust for multiple comparisons.	Genotype AA is not associated with response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotypes AG + GG.	23337555	1183491593
HTRA1	rs11200638	A	ranibizumab	efficacy	no	Age-related macular degeneration. No significant differences in best-corrected visual acuity (BCVA) changes or central subfield macular thickness (CSMT) changes were seen between baseline and 3 or 6 months of treatment between any of the genotypes.	Allele A is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele G.	23559864	1183682052
HTRA1	rs11200638	A	ranibizumab	efficacy	no	Patients underwent 5 monthly injections. Good response at month 5 was defined as best-corrected visual acuity improvement of >= 8 Early Treatment Diabetic Retinopathy Study (ETDRS) letters from baseline. Bonferroni correction for multiple testing.	Allele A is not associated with response to ranibizumab in people with Macular Degeneration as compared to allele G.	23842101	1184510410